Roche Eyes Adjuvant HCC Setting After Phase III Tecentriq Combination Success
But Market Opportunity Limited
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.